Chemotherapy Induced Cardiotoxicity in Breast Cancer PatientsNCT02274480
Diffusion Weighted Imaging as a Biomarker for Detection of Chemotherapy Induced Cardiotoxicity
An observational study of Chemotherapy Induced Cardiotoxicity in Breast Cancer Patients, run by Memorial Sloan Kettering Cancer Center at 2 sites in United States.
Trial summary
The goal of this study is to see if a special type of heart scan called a diffusion weighted magnetic resonance imaging (DW-MRI) that uses extra measurements, can be used to find early signs of heart damage from chemotherapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chemotherapy Induced Cardiotoxicity in Breast Cancer Patients
- What is being tested?
- cardiac MRI with DWI
- Type of treatment
- Medical device
- How many people
- 28 participants
- Where
- 2 sitesUnited States
- Study dates
- 22 Oct 2014to 2 Sep 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who meet the selection criteria will be recruited from the breast medical oncology clinics at MSKCC.
Who may be able to join
- ≥18 years of age on the day of signing the informed consent.
- Diagnosis of HER2+ breast cancer
- History of anthracycline therapy and antiHER2 treatment
- For subjects with decrease in LVEF: Recent (within 12 weeks) drop in LVEF ≥10% on echocardiogram from baseline and confirmed by cardiac MRI for the study population. If the drop in EF is not confirmed on MRI, the subject will be removed and placed into the control group.
- For control group: Less than a 10% change in EF from baseline for the control population confirmed on echocardiogram and cardiac MRI. If no change in EF is not confirmed on MRI, the subject will be removed and placed into the study group if the change in EF is equal to or greater than 10%. Note: Male breast cancer patients are uncommon and are not expected to be included in this study, however if they meet the above criteria, they will not be excluded.
Who cannot join
- Prior myocardial infarction
- Prior surgical or percutaneous coronary revascularization
- Pregnant or lactating patients
- Patients who because of general medical or psychiatric condition, or physiologic status unrelated to the presence of breast cancer cannot give valid informed consent
- Patients who are unwilling or unable to undergo MRI including patients with contraindications to MRI such as the presence of cardiac pacemakers or non-compatible intracranial vascular clips, claustrophobia, inability to lie flat for the duration of the study etc. MRI eligibility will be determined on the day of consent with the MRI questionnaire.
- Patients with metallic implants or device in the chest that might distort local magnetic field and compromise quality of MRI
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Memorial Sloan Kettering Westchester
Harrison, New York, 10604
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
About this study
The goal of this study is to see if a special type of heart scan called a diffusion weighted magnetic resonance imaging (DW-MRI) that uses extra measurements, can be used to find early signs of heart damage from chemotherapy.
Read the detailed description
This prospective single institutional pilot study will enroll breast cancer patients who develop cardiotoxicity while on anthracycline and anti-HER2 therapy . The control group will be composed of patients on similar anthracycline therapy and dose but without a decline in LVEF on Cardiac MRI (CMR). Clinic visits with monitoring for cardiotoxicity occur as part of standard of care after therapy initiation. The study and control group will be composed of 15 patients each. At the discretion of the treating physician, patients will be recruited from the Breast Medical Oncology Service.
- Being tested
- cardiac MRI with DWI
- Keywords
- MRI, Diffusion Weighted Imaging, 14-191
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cardiac MRI with DWIDevice
| Study group | Role | What they receive |
|---|---|---|
| Breast cancer patients with cardiotoxicity | Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete. Receives: Device: cardiac MRI with DWI | |
| Breast cancer patients without cardiotoxicity | Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete. Receives: Device: cardiac MRI with DWI |
What is being measured
The primary outcome is the main question the study is designed to answer.
presence of edema
associated with cardiotoxicity as visualized on DWI by the attending cardiac imagers we may explore the association of the presence of edema on DWI with a drop in LVEF > 10% using exact logistic regression
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Oct 2014 (estimated)
- Study start22 Oct 2014
- Primary completion2 Sep 2020
- Study completion2 Sep 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chemotherapy Induced Cardiotoxicity in Breast Cancer PatientsStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 28 participants (actual)
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Andrew Plodkowski, MD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02274480
- Sponsor's protocol ID
- 14-191
- Status last verified
- Sep 2020
- First submitted
- 22 Oct 2014
- Last updated
- 4 Sep 2020
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diffusion Weighted Imaging as a Biomarker for Detection of Chemotherapy Induced Cardiotoxicity
- ClinicalTrials.gov ID
- NCT02274480
- Acronym / sponsor ID
- 14-191
- Keywords
- MRI, Diffusion Weighted Imaging, 14-191
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 28 participants (actual)
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Study start
- 22 Oct 2014 (actual)
- Primary completion
- 2 Sep 2020 (actual)
- Study completion
- 2 Sep 2020 (actual)
- First posted
- 24 Oct 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to see if a special type of heart scan called a diffusion weighted magnetic resonance imaging (DW-MRI) that uses extra measurements, can be used to find early signs of heart damage from chemotherapy.
Detailed description
This prospective single institutional pilot study will enroll breast cancer patients who develop cardiotoxicity while on anthracycline and anti-HER2 therapy . The control group will be composed of patients on similar anthracycline therapy and dose but without a decline in LVEF on Cardiac MRI (CMR). Clinic visits with monitoring for cardiotoxicity occur as part of standard of care after therapy initiation. The study and control group will be composed of 15 patients each. At the discretion of the treating physician, patients will be recruited from the Breast Medical Oncology Service.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Breast cancer patients with cardiotoxicity | – | Device: cardiac MRI with DWIEach patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete. |
| Breast cancer patients without cardiotoxicity | – | Device: cardiac MRI with DWIEach patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who meet the selection criteria will be recruited from the breast medical oncology clinics at MSKCC.
Key inclusion criteria (5 listed)
- ≥18 years of age on the day of signing the informed consent.
- Diagnosis of HER2+ breast cancer
- For subjects with decrease in LVEF: Recent (within 12 weeks) drop in LVEF ≥10% on echocardiogram from baseline and confirmed by cardiac MRI for the study population. If the drop in EF is not confirmed on MRI, the subject will be removed and placed into the control group.
- For control group: Less than a 10% change in EF from baseline for the control population confirmed on echocardiogram and cardiac MRI. If no change in EF is not confirmed on MRI, the subject will be removed and placed into the study group if the change in EF is equal to or greater than 10%. Note: Male breast cancer patients are uncommon and are not expected to be included in this study, however if they meet the above criteria, they will not be excluded.
Key exclusion criteria (6 listed)
- Prior myocardial infarction
- Prior surgical or percutaneous coronary revascularization
- Pregnant or lactating patients
- Patients who because of general medical or psychiatric condition, or physiologic status unrelated to the presence of breast cancer cannot give valid informed consent
- Patients who are unwilling or unable to undergo MRI including patients with contraindications to MRI such as the presence of cardiac pacemakers or non-compatible intracranial vascular clips, claustrophobia, inability to lie flat for the duration of the study etc. MRI eligibility will be determined on the day of consent with the MRI questionnaire.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| cardiac MRI with DWI | Device | Breast cancer patients with cardiotoxicity, Breast cancer patients without cardiotoxicity |
Primary outcome
presence of edema
Time frame: 1 year
associated with cardiotoxicity as visualized on DWI by the attending cardiac imagers we may explore the association of the presence of edema on DWI with a drop in LVEF > 10% using exact logistic regression
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2020.
- Memorial Sloan Kettering Cancer CenterLink provided by the sponsor.
Related trials for Chemotherapy Induced Cardiotoxicity in Breast Cancer Patients
RecruitingObservational study
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
Cardiotoxicity, Heart Failure
Not yet recruiting
Grape Polyphenols for Prevention of Chemotherapy-Induced Cardiotoxicity
Chemotherapy-induced Cardiotoxicity, Breast Cancer
Not yet recruitingPhase 4
Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients
Anthracycline-induced Cardiac Toxicity, Breast Cancer
RecruitingPhase 2
Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients
Heart Failure, Anthracycline-induced Cardiac Toxicity
Active, not recruitingObservational study
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
Breast Cancer, Cardiotoxicity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andrew Plodkowski, MD principal investigator
Memorial Sloan Kettering Cancer Center
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chemotherapy Induced Cardiotoxicity in Breast Cancer Patients, run by Memorial Sloan Kettering Cancer Center at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
presence of edema (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2020.